Nasal mRNA ETH47 Cuts Rhinovirus Load 40-Fold in Asthma Study

hcplive.com —

Ethris announced on November 5, 2026, that its nasal mRNA therapy ETH47 reduced peak rhinovirus load 40-fold in a 50-patient asthma challenge study, though the primary endpoint of lower respiratory symptom score did not reach statistical significance. The phase 2a trial enrolled adults with asthma who received a single ETH47 dose before rhinovirus A16 challenge. Viral load fell 40-fold at day 2, peak symptom scores dropped 14%, and symptom area under the curve was 58% lower versus placebo. No serious adverse events or systemic exposure were reported. ETH47 encodes interferon lambda to boost local antiviral defense. Exploratory analysis showed greater effects in participants with higher drug exposure, including over 100-fold viral load reduction. Ethris plans further studies in asthma and COPD, plus a room-temperature-stable dry powder formulation.


With a significance score of 2.9, this news ranks in the top 11% of today's 29660 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Nasal mRNA ETH47 Cuts Rhinovirus Load 40-Fold in Asthma Study | News Minimalist